Search Results for: bob lanza

Brief update from Bob Lanza on Astellas stem cell program

Lanza-Astellas

Late in 2015, one of the pioneering stem cell and regenerative medicine biotechs, Ocata Therapeutics (fka as ACT or Advanced Cell Technology) was acquired by Astellas Pharma. At the time of purchase, Ocata had a number of areas of focus, but was most closely followed for its development of human embryonic stem cell-based retinal pigmented epithelial […]

Brief update from Bob Lanza on Astellas stem cell program Read More »

Brief quote from Bob Lanza on Ocata acquisition by Astellas

Dr. Robert Lanza

I asked Ocata CSO, Bob Lanza, for a comment on the big news of the acquisition of the company by Astellas. Here’s what he had to say: “I can say that this is an exciting time for regenerative medicine.  The merger should greatly accelerate the pace of discovery, and, I hope, lead to treatments for

Brief quote from Bob Lanza on Ocata acquisition by Astellas Read More »

Weekly reads: aging cells, scientists relying on ChatGPT, anemone stem cells

cellular aging

Do our aging cells necessitate that we age overall as people? Flipping it around, if we can stop or reverse enough cellular aging, will our overall aging be positively affected? It’s clear that people age very differently from each other and so do our cells and organs. Interestingly, intramurally in a sense the cells and

Weekly reads: aging cells, scientists relying on ChatGPT, anemone stem cells Read More »

Recent stem cell pubs & news: reprogramming, chromatin, single-cell, Astellas, & more

stem-cell-news-pigs-organ-transplants

What new papers and news in the stem cell sphere caught your eye? Here are some recent items that seem notable to me. Diabetes relief in mice by glucose-sensing insulin-secreting human α-cells. This paper reports cellular reprogramming to insulin-producing cells in mice. They reprogrammed α-cells with Pdx1 and MafA proteins. ‘Mitophagy inhibits amyloid-β and tau pathology and reverses

Recent stem cell pubs & news: reprogramming, chromatin, single-cell, Astellas, & more Read More »

ACT reinventing itself with new name Ocata Therapeutics

advanced-cell-technology

Here is a link to the Ocata website, marking the start of a new era for what was formerly Advanced Cell Technology or ACT. It’s been a big summer for stem cell biotech Advanced Cell Technology (ACT; stock ACTCD) as it continues what I would call a process of reinventing itself. What’s been happening? ACT recently

ACT reinventing itself with new name Ocata Therapeutics Read More »